ストックスクリーナーアプリを入手
6.70
0.45%
0.03
前日終値:
$6.67
開ける：
$6.64
24時間の取引高:
717.29K
Relative Volume:
0.37
時価総額：
$987.43M
収益：
$62.04M
当期純損益:
$-533.34M
株価収益率:
-1.7092
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
-3.32%
1か月 パフォーマンス:
-17.39%
6か月 パフォーマンス:
-11.02%
1年 パフォーマンス:
-33.86%
1日の値動き範囲:
$6.515
$6.71
1週間の範囲:
$6.40
$7.22
52週間の値動き範囲:
$6.40
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
VIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
6.70 | 987.43M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo Finance
Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India
(VIR) Trading Advice - Stock Traders Daily
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow
(VIR) Trading Signals - Stock Traders Daily
Morgan Stanley maintains $20 target on Vir Biotechnology stock By Investing.com - Investing.com Canada
Morgan Stanley maintains $20 target on Vir Biotechnology stock - Investing.com India
Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection - Marketscreener.com
Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial -March 13, 2025 at 08:30 am EDT - Marketscreener.com
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com
SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $35.67 - Defense World
Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN
Principal Financial Group Inc. Has $3.28 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund - Defense World
Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology's (VIR) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
What is HC Wainwright’s Forecast for VIR Q1 Earnings? - Defense World
(VIR) On The My Stocks Page - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for Vir Biotechnology (NASDAQ:VIR) - Defense World
Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating - TipRanks
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, Barclays Analyst Says - Defense World
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Canada Finance
7 Analysts Have This To Say About Vir Biotechnology - Benzinga
Decoding Vir Biotechnology Inc (VIR): A Strategic SWOT Insight - GuruFocus.com
Vir Biotechnology’s Transformative Year: Earnings Call Insights - TipRanks
Vir Biotechnology Becomes Oversold (VIR) - Nasdaq
Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock By Investing.com - Investing.com Canada
Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock - Investing.com India
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript - Insider Monkey
Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology - TipRanks
Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
Vir Biotechnology: Balancing Long-term Potential with Near-term Uncertainty – A Hold Rating Analysis - TipRanks
Vir Biotechnology, Inc. SEC 10-K Report - TradingView
Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - BioSpace
Vir Biotechnology Reports 2024 Financial Results and Strategic Advances - TipRanks
Vir Biotechnology: Strong Financial Position and Promising Pipeline Justify Buy Rating - TipRanks
Earnings call transcript: Vir Biotech beats Q4 2024 forecasts, stock rises - Investing.com India
Vir Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vir Biotechnology reports Q4 EPS (76c), consensus (87c) - TipRanks
Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 11c - StreetInsider.com
Vir Biotechnology CEO sells $152,407 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology's SVP sells shares worth $14,766 By Investing.com - Investing.com Canada
Vir Biotechnology EVP vanina de Verneuil sells $48,590 in shares By Investing.com - Investing.com Australia
Vir Biotechnology EVP sells shares worth $133,935 By Investing.com - Investing.com Australia
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):